Literature DB >> 26437058

Cerebrospinal fluid chimerism analysis in patients with neurological symptoms after allogeneic cell transplantation.

M Waterhouse1, I Bartsch1,2, H Bertz1, J Duyster1, J Finke1.   

Abstract

Central nervous system (CNS) complications have been described in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT). Cerebrospinal fluid (CSF) analysis is included in the diagnostic workup in patients with neurological symptoms after alloHCT. CSF donor-recipient chimerism analysis usually is not used to evaluate patients with neurological complications after alloHCT. To assess the potential contribution of CSF donor-recipient chimerism in patients with neurological complications, we analyzed 85 CSF samples from 50 patients with neurological complications after alloHCT. After alloHCT, 21 patients showed the presence of recipient-derived DNA. In 13 of these patients, recurrence of the underlying disease was detected in CSF. There was a moderate correlation between the recipient DNA percentage as detected by short tandem repeat (STR) amplification and the cell concentration in CSF (Spearmann r: 0.66 P=0.004). The percentage of cells with immunophenotypic abnormalities from patients relapsing in the CNS detected by flow cytometry showed a strong correlation with the percentage of recipient-derived DNA in CSF assessed by STR analysis (Spearmann r: 0.83 P=0.0008). Donor-recipient chimerism analysis in CSF in patients with neurological symptoms after alloHCT is a practical, feasible and useful complementary method to the already established methodologies included in the diagnostic workup.

Entities:  

Mesh:

Year:  2015        PMID: 26437058     DOI: 10.1038/bmt.2015.226

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  Reliability of quantitative chimerism results: assessment of sample performance using novel parameters.

Authors:  D Kristt; T Klein
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

2.  Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?

Authors:  M Dissing; M M Le Beau; J Pedersen-Bjergaard
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation.

Authors:  Miguel Waterhouse; Regina Kunzmann; Marta Torres; Hartmut Bertz; Juergen Finke
Journal:  Clin Chem Lab Med       Date:  2013-02       Impact factor: 3.694

4.  Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases.

Authors:  Haruhiko Ohashi; Chiaki Kato; Shoko Fukami; Hidehiko Saito; Motohiro Hamaguchi
Journal:  Am J Hematol       Date:  2005-06       Impact factor: 10.047

5.  Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes.

Authors:  Joachim M Baehring; Fred H Hochberg; Rebecca A Betensky; Janina Longtine; Jeffrey Sklar
Journal:  J Neurol Sci       Date:  2006-06-09       Impact factor: 3.181

6.  Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation.

Authors:  Alexandros Spyridonidis; Robert Zeiser; Ralph Wäsch; Hartmut Bertz; Jürgen Finke
Journal:  Clin Transplant       Date:  2005-06       Impact factor: 2.863

7.  Detection of malignant B lymphocytes by PCR clonality assay using direct lysis of cerebrospinal fluid and low volume specimens.

Authors:  L Liu; F Cao; S Wang; J Zhou; G Yang; C Wang
Journal:  Int J Lab Hematol       Date:  2014-05-12       Impact factor: 2.877

8.  Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

Authors:  Reinhard Marks; Karin Potthoff; Joachim Hahn; Gabriele Ihorst; Hartmut Bertz; Alexandros Spyridonidis; Ernst Holler; Jürgen M Finke
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

9.  Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.

Authors:  Deborah Siegal; Anne Keller; Wei Xu; Sandeep Bhuta; Dong Hwan Kim; John Kuruvilla; Jeffrey H Lipton; Hans Messner; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-21       Impact factor: 5.742

10.  CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.

Authors:  J E C Bromberg; D A Breems; J Kraan; G Bikker; B van der Holt; P Sillevis Smitt; M J van den Bent; M van't Veer; J W Gratama
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

View more
  3 in total

1.  Donor cell chimerism evaluation in cerebrospinal fluid by short tandem repeat analysis following allogeneic hematopoietic stem cell transplantation.

Authors:  Jessica L Spruit; Omar R Fagoaga; Süreyya Savaşan
Journal:  Hum Immunol       Date:  2018-04-11       Impact factor: 2.850

2.  Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma.

Authors:  Thomas Mika; Swetlana Ladigan; Alexander Baraniskin; Deepak Vangala; Sabine Seidel; Olaf Hopfer; Michael Kiehl; Roland Schroers
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

3.  Low donor chimerism may be sufficient to prevent demyelination in adrenoleukodystrophy.

Authors:  Takahiro Ikeda; Yuta Kawahara; Akihiko Miyauchi; Hitomi Niijima; Rieko Furukawa; Nobuyuki Shimozawa; Akira Morimoto; Hitoshi Osaka; Takanori Yamagata
Journal:  JIMD Rep       Date:  2021-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.